Corporate practices and health: a framework and mechanisms

J Madureira Lima, S Galea - Globalization and Health, 2018 - Springer
Abstract Background The Global Burden of Disease estimates that approximately a third of
deaths worldwide are attributable to behavioural risk factors that, at their core, have the …

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

B Godman, RE Malmström, E Diogene… - Expert review of …, 2015 - Taylor & Francis
Medicines have made an appreciable contribution to improving health. However, even high-
income countries are struggling to fund new premium-priced medicines. This will grow …

Hate speech on social media: Content moderation in context

RA Wilson, MK Land - Conn. L. Rev., 2020 - HeinOnline
Hate speech and hate crimes are trending. In the past five years, there has been an upsurge
in extreme nationalist and nativist political ideology in mainstream politics globally. In the …

Institutional corruption of pharmaceuticals and the myth of safe and effective drugs

DW Light, J Lexchin, JJ Darrow - Journal of Law, Medicine & Ethics, 2013 - cambridge.org
Institutional corruption is a normative concept of growing importance that embodies the
systemic dependencies and informal practices that distort an institution's societal mission …

[HTML][HTML] ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe

N Cherny, R Sullivan, J Torode, M Saar, A Eniu - Annals of Oncology, 2016 - Elsevier
Background The management of cancer is predicated on the availability and affordability of
anticancer therapies, which may be either curative or noncurative. Aim The primary aims of …

Mapping conflict of interests: scoping review

S Chimonas, M Mamoor, SA Zimbalist, B Barrow… - bmj, 2021 - bmj.com
Objective To identify all known ties between the medical product industry and the healthcare
ecosystem. Design Scoping review. Methods From initial literature searches and expert …

Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities

GA Van Norman - Basic to Translational Science, 2023 - jacc.org
Once medical drugs and devices are approved for marketing by the FDA they can legally be
used for purposes and in ways other than the ones for which they have been tested and …

Prevalence of third-party tracking on abortion clinic web pages

AB Friedman, L Bauer, R Gonzales… - JAMA Internal …, 2022 - jamanetwork.com
Methods| In this cross-sectional study, we extracted the uniform resource locator (URL) of
each National Abortion Federation member facility on May 6, 2022. 5 We visited each …

Market failures and market framings: Can a market be transformed from the inside?

S Geiger, N Gross - Organization Studies, 2018 - journals.sagepub.com
How do actors innovate markets in cases of perceived market failures? This paper's aim is to
examine what happens when a market is innovated or, as we call it,'redevised'in situations …

[HTML][HTML] Innovation and misconduct in the pharmaceutical industry

DG Arnold, LH Amato, JL Troyer, OJ Stewart - Journal of Business …, 2022 - Elsevier
The relationships between innovation and firm misconduct have received little attention. We
contribute to advancing understanding of misconduct in several ways. First, we find support …